CAS: 305350-87-2; 3-Amino-3-((4-Aminophenyl)Thio)-2-(2-(Trifluoromethyl)Phenyl)Acrylonitrile

该化合物是一种化学化合物,其结构复杂,包括一个氨基氨基化合物组,硫醚联系和三氟甲基组.该化合物的特性是用三氟甲基组和硝三氟基苯组替代的苯环,这有利于其独特的化学反应和药用化学的潜在应用.氨基和硫醚的功能表明它可能参与各种化学反应,如核生殖器替代或混合反应.此外,已知三氟甲基组可增强脂性和代谢稳定性,使这种化合物在药物设计中产生兴趣.该化合物的具体特性,如溶性,熔化点和再活性,将取决于其分子相互作用和研究的环境.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

C&L通报

上下游产品

2-[2-[(trifluoromethyl)phenyl]]propanedinitrile malononitrile 4-aminotiophenol 2-iodo(trifluoromethyl)benzene

合成工艺路线路线简述

    📜2-[2-[(Trifluoromethyl)Phenyl]]Propanedinitrile,丙二腈,4-氨基苯硫酚置于三乙胺体系中,用 四氢呋喃,正己烷,乙酸乙酯 作为反应溶剂,化学反应生成 Alpha-[氨基[(4-氨基苯基)硫代]亚甲基]-2-(三氟甲基)苯乙腈
    参考文献:Methods For Treating Seizure Disorders By Inhibiting Mapk Pathway Activation
    标题:Methods For Treating Seizure Disorders By Inhibiting Mapk Pathway Activation
    摘要:过度的脑神经兴奋,与癫痫病有关,可能与神经元中丝裂原活化蛋白激酶(mapk)的活性增加相关.通过给患有癫痫病的个体施用有效量的化合物,如mapk磷酸化或激酶活性抑制剂,可以减少神经元中mapk活性的数量,从而改善这种过度的兴奋.抑制mapk级联的上游激活剂或下游靶标的磷酸化或激酶活性的化合物在这种情况下也是有用的.

    海关参考信息

    专利信息


    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    专利号:CN-108379591-B
    优先权日:2018-04-03
    标 题 :Synthesis of Immune Agonist Targeting Compounds and Their Applications

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Chen B, Zhao C, Zhu H, Lu X, Liu H, Lu Q, Zhu T, Huang C. β-glucan, a specific immuno-stimulant, produces rapid antidepressant effects by stimulating ERK1/2-dependent synthesis of BDNF in the hippocampus. Eur J Pharmacol. 2023 Dec 15;961:176161. doi: 10.1016/j.ejphar.2023.176161. Epub 2023 Nov 7.
    957:176038. doi: 10.1016/j.ejphar.2023.176038. Epub 2023 Aug 30. 1870(8):119542. doi: 10.1016/j.bbamcr.2023.119542. Epub 2023 Jul 18.
    319:121529. doi: 10.1016/j.lfs.2023.121529. Epub 2023 Feb 23. 87(2):191-196. doi: 10.1093/bbb/zbac192.

    合成参考文献


    参考文献:10.1046/j.0022-3042.2001.00753.x
    摘要:Yamagata Y, Jovanovic JN, Czernik AJ, Greengard P, Obata K. Bidirectional changes in synapsin I phosphorylation at MAP kinase‐dependent sites by acute neuronal excitation in vivo. Journal of Neurochemistry. 2002 Mar;80(5):835–42. doi: 10.1046/j.0022-3042.2001.00753.x.
    参考文献:10.1006/bbrc.2001.5482
    摘要:Wang H, Xu L, Venkatachalam S, Trzaskos JM, Friedman SM, Feuerstein GZ, Wang X. Differential regulation of IL-1beta and TNF-alpha RNA expression by MEK1 inhibitor after focal cerebral ischemia in mice. Biochem Biophys Res Commun. 2001 Sep 07;286(5):869–74. doi: 10.1006/bbrc.2001.5482.
    参考文献:10.1016/j.cellsig.2012.12.006
    摘要:Halleskog C, Schulte G. Pertussis toxin-sensitive heterotrimeric G(αi/o) proteins mediate WNT/β-catenin and WNT/ERK1/2 signaling in mouse primary microglia stimulated with purified WNT-3A. Cell Signal. 2013 Apr;25(4):822–8. doi: 10.1016/j.cellsig.2012.12.006.
    参考文献:10.1093/ijnp/pyx005
    摘要:Borges G, Miguelez C, Neto F, Mico JA, Ugedo L, Berrocoso E. Activation of Extracellular Signal-Regulated Kinases (ERK 1/2) in the Locus Coeruleus Contributes to Pain-Related Anxiety in Arthritic Male Rats. Int J Neuropsychopharmacol. 2017 Jun 01;20(6):463.
    参考文献:10.1016/j.biopha.2017.01.135
    摘要:Wang W, Zhou J, Zhao L, Chen S. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells. Biomed Pharmacother. 2017 Apr;88():985–90. doi: 10.1016/j.biopha.2017.01.135.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知